Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.
2.

Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.

Wood SJ, Berger GE, Lambert M, Conus P, Velakoulis D, Stuart GW, Desmond P, McGorry PD, Pantelis C.

Arch Gen Psychiatry. 2006 Sep;63(9):969-76.

PMID:
16952999
3.

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.

Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B.

J Psychiatr Res. 2007 Oct;41(8):625-34. Epub 2006 Sep 1.

PMID:
16949099
4.

Regulation of N-acetylaspartate and N-acetylaspartylglutamate biosynthesis by protein kinase activators.

Arun P, Madhavarao CN, Moffett JR, Namboodiri MA.

J Neurochem. 2006 Sep;98(6):2034-42.

5.

Aspartoacylase is a regulated nuclear-cytoplasmic enzyme.

Hershfield JR, Madhavarao CN, Moffett JR, Benjamins JA, Garbern JY, Namboodiri A.

FASEB J. 2006 Oct;20(12):2139-41. Epub 2006 Aug 25.

PMID:
16935940
7.

Proton magnetic resonance spectroscopy in subjects at risk for schizophrenia.

Jessen F, Scherk H, Träber F, Theyson S, Berning J, Tepest R, Falkai P, Schild HH, Maier W, Wagner M, Block W.

Schizophr Res. 2006 Oct;87(1-3):81-8. Epub 2006 Jul 13.

PMID:
16842971
8.

Hypoacetylaspartia: clinical and biochemical follow-up of a patient.

Burlina AP, Schmitt B, Engelke U, Wevers RA, Burlina AB, Boltshauser E.

Adv Exp Med Biol. 2006;576:283-7; discussion 361-3. No abstract available.

PMID:
16802720
9.
10.

Anaplerotic molecules: current and future.

Brunengraber H, Roe CR.

J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):327-31. Review.

PMID:
16763895
11.

Quantitative magnetic resonance spectroscopy of schizophrenia: relationship between decreased N-acetylaspartate and frontal lobe dysfunction.

Tanaka Y, Obata T, Sassa T, Yoshitome E, Asai Y, Ikehira H, Suhara T, Okubo Y, Nishikawa T.

Psychiatry Clin Neurosci. 2006 Jun;60(3):365-72.

12.

N-acetylaspartate as a reservoir for glutamate.

Clark JF, Doepke A, Filosa JA, Wardle RL, Lu A, Meeker TJ, Pyne-Geithman GJ.

Med Hypotheses. 2006;67(3):506-12. Epub 2006 May 26.

PMID:
16730130
13.

Correlation of cerebral metabolites with functional outcome in experimental primate stroke using in vivo 1H-magnetic resonance spectroscopy.

Coon AL, Arias-Mendoza F, Colby GP, Cruz-Lobo J, Mocco J, Mack WJ, Komotar RJ, Brown TR, Connolly ES Jr.

AJNR Am J Neuroradiol. 2006 May;27(5):1053-8.

14.

Canavan disease and the role of N-acetylaspartate in myelin synthesis.

Namboodiri AM, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN.

Mol Cell Endocrinol. 2006 Jun 27;252(1-2):216-23. Epub 2006 May 2. Review.

PMID:
16647192
15.

Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.

Mostert JP, Sijens PE, Oudkerk M, De Keyser J.

Neurosci Lett. 2006 Jul 10;402(1-2):22-4. Epub 2006 Apr 27.

PMID:
16644118
16.

Is NAA reduction in normal contralateral cerebral tissue in stroke patients dependent on underlying risk factors?

Walker PM, Ben Salem D, Giroud M, Brunotte F.

J Neurol Neurosurg Psychiatry. 2006 May;77(5):596-600.

17.

What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.

Abbott C, Bustillo J.

Curr Opin Psychiatry. 2006 Mar;19(2):135-9. Review.

PMID:
16612192
18.

Hypothalamic hamartomas: Correlation of MR imaging and spectroscopic findings with tumor glial content.

Amstutz DR, Coons SW, Kerrigan JF, Rekate HL, Heiserman JE.

AJNR Am J Neuroradiol. 2006 Apr;27(4):794-8.

19.

Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis.

Mathiesen HK, Jonsson A, Tscherning T, Hanson LG, Andresen J, Blinkenberg M, Paulson OB, Sorensen PS.

Arch Neurol. 2006 Apr;63(4):533-6.

PMID:
16606765
20.

Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex.

Marenco S, Steele SU, Egan MF, Goldberg TE, Straub RE, Sharrief AZ, Weinberger DR.

Am J Psychiatry. 2006 Apr;163(4):740-2.

Supplemental Content

Support Center